MBTPS2 and neoplasm: Preclinical results showed that 177Lu2O3-iPSMA and 177Lu2O3-iFAP inhibit colorectal HCT116 tumor progression due to prolonged tumor retention and a combination of 177Lu radiotherapy and iPSMA or iFAP molecular recognition.